Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inflammation-driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients.

British journal of clinical pharmacology - 1 Jul 2026

Klomp Sylvia D, Manson Martijn L, Guchelaar Henk-Jan, Böhringer Stefan, van Egmond Esther H M, von dem Borne Peter A, Swen Jesse J

Abstract excerpt

AIMS: Voriconazole is commonly used to prevent fungal infections after haematopoietic stem cell transplantation (HSCT). Although its metabolism is influenced by CYP2C19 genetics and inflammation, their combined effect is rarely considered in clinical practice, and integrated analyses remain limited. METHODS: We retrospectively analysed how inflammation and CYP2C19-predicted drug-metaboliser phenotypes affect...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal Agents
Share to C-Reactive Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Hematopoietic Stem Cell Transplantation

Share to Inflammation

Share to Mycoses

Share to Phenotype

Share to Voriconazole

Source

Open in PubMed Open full text

Identifiers

PMID: 41766069
DOI: 10.1002/bcp.70501
PMCID: PMC13304255

Genes

CYP2C19
CRP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inflammation-driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients.PMID 41766069Read ↗

Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole.Semantic proximity Read ↗

Pharmacogenomic Profiling of Voriconazole Enables Predicting Its Toxicity in Pediatric Leukemia and Hematopoietic Stem Cell Transplant Recipients-A Prospective Study From North India.Semantic proximity Read ↗

Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.Semantic proximity Read ↗

<i><scp>CYP</scp>2C19</i> Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?Semantic proximity Read ↗

Individualized treatment with voriconazole in the Chinese population: Inflammation level as a novel marker for dose optimization.Semantic proximity Read ↗

Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations.Semantic proximity Read ↗

The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.Semantic proximity Read ↗

Predictors of tacrolimus dose optimization when drug-drug interaction associated with voriconazole in heart transplant recipientsSemantic proximity Read ↗

Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysisSemantic proximity Read ↗

Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers.Semantic proximity Read ↗

Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.Semantic proximity Read ↗

Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.